Moderator Message:
I moved this from the Autumn booster thread as it could lead that thread off topic.
I moved this from the Autumn booster thread as it could lead that thread off topic.
redsturgeon wrote:scotia wrote:scotia wrote:I don't know the status of various medicine journals - but why is this study presented in a journal of insulinresistance?
Possibly the answer to my question is the fact that the author of the paper (Aseem Alhotra) is on the Editorial Board of the journal of insulinresistance.
I would feel much happier if it were published in an independent journal, and one which is relevant to Covid Vaccines. The stated field of interest of the publishing journal isadvances in disorders of insulin resistance
I would be happier too but I think he raises some interesting questions.
John
Here's another scientific paper looking at potential issues with mRNA vaccines.
https://www.sciencedirect.com/science/a ... 1422001897
Their concluding remarks:
Concluding remarks and future perspectives
Such considerations as a whole support the possibility that COVID-19 mRNA vaccines under some circumstances induce high and possibly toxic amounts of S protein in organs and tissues, in turn leaking into the circulation. In animal models, it is well established that lipid nanoparticle-carried mRNAs undergo systemic disposition and expression in organs such as liver, skeletal muscle, and lungs [13]. It can be suggested that at least part of the risk to develop adverse reactions following vaccination with mRNA products depends on the organs/tissues where S protein production occurs, as well as on the total amount produced and on the production time course. For example, it was established long ago that distinct tissues widely differ in the efficiency of protein synthesis, but no one so far assessed whether and to what extent this is relevant for the efficacy and safety of mRNA vaccines [13]. Therefore, we further recommend careful characterization of COVID-19 vaccines with regards to systemic disposition, including organs and tissues where S protein production occurs and interindividual variability in local protein synthesis efficiency, to provide a rational basis for dose individualization and to identify subjects at risk for adverse reactions due to either vaccine-induced S protein production in vulnerable sites, excessive S protein production, or both
Overall my conclusion is that now the emergency situation regarding the covid epidemic has subsided, much more research is needed before continued widespread use of mRNA vaccines in large non vulnerable populations.
John